Press Releases April 20, 2026 04:05 PM

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation announces inducement stock option grants to nine new employees under Nasdaq rules

By Caleb Monroe GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERN

Geron Corporation, a biopharmaceutical company, reported the granting of stock options totaling 855,000 shares to nine newly hired employees as inducements to join the firm. The options, priced at $1.68 per share, vest over four years and align with Nasdaq Listing Rule 5635(c)(4). Geron continues its efforts with its approved drug RYTELO® for blood cancers and ongoing pivotal Phase 3 trials.

Key Points

  • Geron granted stock options for 855,000 shares to nine new employees as inducements.
  • Options have a $1.68 exercise price, ten-year term, and four-year vesting schedule.
  • Geron is a commercial-stage biopharmaceutical firm with an approved drug and ongoing clinical trials in blood cancers.

FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]


Risks

  • The inducement awards depend on continued employment, creating retention risk if employees depart early.
  • The stock options issued could dilute existing shareholders when exercised, potentially impacting the stock price.
  • Uncertainties around the clinical trial outcomes for imetelstat in myelofibrosis could affect future company prospects.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026